

Haematologica  
HAEMATOL/2017/164996  
Version 3

Development of a modified prognostic index of patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: a possible risk-adapted management strategies including allogeneic transplantation

Shigeo Fuji, Takuhiro Yamaguchi, Yoshitaka Inoue, Atae Utsunomiya, Yuki Yoshi Moriuchi, Kaoru Uchimarui, Satsuki Owatari, Takashi Miyagi, Jun Taguchi, Ilseung Choi, Eiichi Otsuka, Sawako Nakachi, Hisashi Yamamoto, Saiko Kurosawa, Kensei Tobinai, and Takahiro Fukuda

Disclosures: S.F. received honoraria from Kyowa Hakko Kirin Co., Ltd.; T.Y. had ownership interests of Statcom Co., Ltd., received consulting fee from Ono Pharmaceutical Co., Ltd., received honoraria from Taiho Pharmaceutical Co., Ltd. and received research funding from Kyowa Hakko Kirin Co., Ltd.; A.U. received honoraria from Kyowa Hakko Kirin Co., Ltd.; K.U. received research funding from Daiichi Sankyo Co., Ltd.; K.T. received honoraria from Zenyaku Kogyo, Eisai, Takeda, Mundipharma, Janssen and HUYA Bioscience International, received research funding from Chugai Pharma, Kyowa Hakko Kirin, Ono Pharmaceutical, Celgene, Janssen, GlaxoSmithKline, Eisai, Mundipharma, Takeda, SERVIER and Abbvie.

Contributions: S.F., T.Y., Y.I., and T.F. participated in research design, data analysis, and manuscript writing. S.K. and K.T. participated in research design and manuscript writing. A.U., Y.M., K.U., S.H., T.M., J.T., I.C., E.O., T.T., and H.Y. gathered the data. All authors approved the submission of this manuscript.